Natural Adjuvants to Enhance Efficacy of Viral Vaccines for Mariculture

Award Information
Agency:
Department of Commerce
Branch
National Oceanic and Atmospheric Administration
Amount:
$298,427.00
Award Year:
2011
Program:
SBIR
Phase:
Phase II
Contract:
WC133R-10-CN-0227
Award Id:
n/a
Agency Tracking Number:
10-96
Solicitation Year:
2010
Solicitation Topic Code:
8.1.2.F
Solicitation Number:
1
Small Business Information
17306 NE 26th St, Redmond, WA, 98052-5848
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
179038190
Principal Investigator:
David Powell
VP, Research and Development
(425) 883-9896
davidp@profishent.com
Business Contact:
Roger Palm
President
(425) 883-9896
rogerp@profishent.com
Research Institution:
n/a
Abstract
Marine aquaculture production now exceeds 20 million metric tons annually (FAO 2010) but viral diseases are still a major threat to the expansion of sustainable mariculture systems (National Marine Fisheries Service 2007). Pathogenic viruses continue to devastate many fish and shellfish operations every year (ICES Mariculture Committee 2004, Lightner 2011). To date, vaccines against aquatic animal viruses have generally provided poor protection, are too expensive, and/or must be injected intramuscularly (e.g., DNA vaccines). In response, we will expand and intensify development of innovative biological adjuvant systems initiated in our Phase I trials. We discovered that unique natural marine and terrestrial micro-structures bound to viral antigens can be delivered to gills and mucosal surfaces of salmon to boost specific immune responses against a viral pathogen. We use a nanotechnology-based dynamic light scattering laser instrument to verify attachment of viral antigens or DNA vaccines. Interferon-associated genes and specific antibody titers will be measured by quantitative PCR, ELISA, and virus neutralization tests. Needle-less, immersion immunizations with test formulations will be assessed in fish for safety and efficacy. Multiple, additional in vivo pathogen challenges will be conducted to evaluate new prototype vaccines for relative efficacy and commercialization potential in Phase III field trials.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government